Holen Sie sich die Stockscreener-App
18.44
1.60%
-0.30
Schlusskurs vom Vortag:
$18.74
Offen:
$18.69
24-Stunden-Volumen:
836.71K
Relative Volume:
1.69
Marktkapitalisierung:
$1.14B
Einnahmen:
Nettoeinkommen (Verlust:
$-209.84M
KGV:
-4.035
EPS:
-4.57
Netto-Cashflow:
$-6.73M
1W Leistung:
-12.52%
1M Leistung:
-24.83%
6M Leistung:
-31.70%
1J Leistung:
+0.00%
1-Tages-Spanne:
$17.49
$18.80
1-Wochen-Bereich:
$17.49
$21.26
52-Wochen-Spanne:
$16.50
$34.89
Damora Therapeutics Inc Stock (DMRA) Company Profile
Firmenname
Damora Therapeutics Inc
Sektor
Branche
Telefon
(781) 281-9020
Adresse
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
18.44 | 1.14B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-27 | Eingeleitet | Jefferies | Buy |
| 2026-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-06-08 | Eingeleitet | TD Cowen | Buy |
| 2026-05-28 | Eingeleitet | Wedbush | Outperform |
| 2026-04-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2026-02-17 | Eingeleitet | UBS | Buy |
| 2026-01-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Eingeleitet | Guggenheim | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | BofA Securities | Buy |
| 2020-11-23 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-23 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Damora Therapeutics Inc Aktie (DMRA) Neueste Nachrichten
Breaking News about Damora Therapeutics, Inc.Ordinary Shares (Nasdaq:DMRA) - FinancialContent
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares - Investing.com
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares By Investing.com - Investing.com South Africa
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares By Investing.com - Investing.com India
Using personal funds, CEO Jennifer Jarrett buys Damora Therapeutics (DMRA) shares at $20.23 each. - Stock Titan
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Damora (DMRA) Update: Gains 1.68% to Reach $30.82 in the Current Update; Price Setup: the Near-Term Reference Band Stretches From $29.28 to $32.36 on the DayStrong Buy Stocks - vinanet.vn
Damora (DMRA) Results at a Glance: The Available Earnings Metric Delivers a Miss in the Current Update; Session Move: The Share Price Sheds 6.23% in Latest TradingEarnings Decline Risk - vinanet.vn
DAMORA THERAPEUT (DMRA) Stock News, Mar 19-23, 2026 - Stock Titan
Damora Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus - Sahm
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneVolatility Smirk - vinanet.vn
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneDark Pool Volume - dars.gov.et
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesKAMA Signal - dars.gov.et
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesFear Greed Index - vinanet.vn
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesSuperTrend - careplusvn.com
Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares - kalkinemedia.com
Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan
Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng - Stock Titan
DMRA Q1 2026 Earnings: EPS Misses Estimates by 56.8% as Shares Rise 8%Fiscal Year Earnings - vinanet.vn
Equities Analysts Offer Predictions for DMRA Q3 Earnings - MarketBeat
Damora Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside - Seeking Alpha
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
DMRA SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million - scanx.trade
Damora Therapeutics Q2 Results: EPS beats estimate, losses narrow - scanx.trade
Damora Therapeutics (NASDAQ: DMRA) resets $150M ATM after Cayman redomestication - Stock Titan
Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Damora Starts DMR-001 Trial With 100 mg Monthly Dose - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)? - simplywall.st
DMRA Q1 2026 Earnings: Wider-than-Expected Loss Signals Rising Clinical-Stage Cost PressuresQuarterly Earnings - vinanet.vn
Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - marketbeat.com
Damora initiates phase 1 trial of mutCALR antibody therapy - Investing.com
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com Australia
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila Times
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com UK
Damora Begins Testing Antibody Designed for Monthly Doses - Stock Titan
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com India
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com Australia
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com
DMRA Q2'26 Earnings: EPS estimate is (0.41) USD - TradingView
Finanzdaten der Damora Therapeutics Inc-Aktie (DMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Damora Therapeutics Inc-Aktie (DMRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Firmani Lori | Officer |
Aug 05 '26 |
Proposed Sale |
31.10 |
1,800 |
55,980 |
0 |
| Winslow Garrett | General Counsel |
Jul 06 '26 |
Sale |
29.98 |
245 |
7,345 |
2,289 |
| Firmani Lori | Officer |
Jun 22 '26 |
Proposed Sale |
25.36 |
7,615 |
193,140 |
0 |
| Bruno Julianne | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
129,000 |
0 |
137,032 |
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
6.61%
0.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):